Empowered Funds LLC trimmed its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 11.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 290,626 shares of the company's stock after selling 39,155 shares during the period. Empowered Funds LLC owned about 0.21% of Vir Biotechnology worth $2,133,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Blue Trust Inc. boosted its position in Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company's stock worth $30,000 after purchasing an additional 2,351 shares during the last quarter. Public Sector Pension Investment Board boosted its position in Vir Biotechnology by 1.4% in the third quarter. Public Sector Pension Investment Board now owns 194,208 shares of the company's stock worth $1,455,000 after purchasing an additional 2,600 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Vir Biotechnology by 11.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 29,202 shares of the company's stock worth $214,000 after purchasing an additional 2,922 shares during the last quarter. KBC Group NV boosted its position in Vir Biotechnology by 136.5% in the fourth quarter. KBC Group NV now owns 8,970 shares of the company's stock worth $66,000 after purchasing an additional 5,177 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of Vir Biotechnology by 1.3% during the 3rd quarter. Barclays PLC now owns 550,186 shares of the company's stock valued at $4,121,000 after buying an additional 7,287 shares in the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In related news, Director Vicki L. Sato sold 10,960 shares of the business's stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total transaction of $137,219.20. Following the completion of the transaction, the director now owns 1,312,391 shares in the company, valued at $16,431,135.32. The trade was a 0.83 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 12,598 shares of company stock valued at $152,136. 15.60% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on VIR shares. Barclays lowered their price objective on Vir Biotechnology from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Monday, November 4th. JPMorgan Chase & Co. lifted their price objective on Vir Biotechnology from $10.00 to $14.00 and gave the company a "neutral" rating in a research report on Thursday, January 9th. Leerink Partners lifted their price objective on Vir Biotechnology from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Monday, January 13th. Needham & Company LLC reaffirmed a "buy" rating and set a $19.00 price objective on shares of Vir Biotechnology in a research report on Wednesday, November 20th. Finally, Morgan Stanley raised Vir Biotechnology from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $10.00 to $20.00 in a research report on Thursday, January 9th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $34.83.
Read Our Latest Report on Vir Biotechnology
Vir Biotechnology Trading Up 1.6 %
VIR traded up $0.15 on Tuesday, hitting $9.80. 290,249 shares of the company's stock traded hands, compared to its average volume of 2,830,434. Vir Biotechnology, Inc. has a one year low of $6.56 and a one year high of $14.45. The company's 50 day simple moving average is $9.14 and its 200-day simple moving average is $8.46. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of -2.50 and a beta of 0.64.
About Vir Biotechnology
(
Free Report)
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Featured Articles
Before you consider Vir Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vir Biotechnology wasn't on the list.
While Vir Biotechnology currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
